Informationes plurimae ― Latine

Urticarial vasculitis rara condicio est chronicis vel recurrentibus episodiis notata. Cum eius cutis indicia possunt similes urticariae chronicae, unica sunt, quia lesiones inhaerent circa viginti quattuor horas saltem et post evanescens hyperpigmentatio (hyperpigmentation) causare possunt. Etsi saepe ignotae causae sunt, interdum quibusdam medicamentis, infectionibus, morbis autoimmunes, myelodysplasticis, vel carcinomatis urguetur. Quaedam studia etiam cum COVID-19 et influenza A/H1N1 (influenza A/H1N1). Etiam afficit alias partes corporis sicut musculi, renes, pulmones, gastrointestinalis (gastrointestinal) et oculi; Leukocytoclastic vasculitis (leukocytoclastic vasculitis) in examinatione histopathologica diagnostic est, non semper apparens. Curatio typice incipit cum antibiotica (antibiotics), dapsone (dapsone), colchicina (colchicine), vel hydroxychloroquina (hydroxychloroquine) in levioribus casibus. Ad casus graviores, medicamenta quae systema immune supprimunt sicut methotrexatum (methotrexate), mycophenolate mofetil (mycophenolate mofetil), azathioprum (azathioprine), cyclosporinum (cyclosporine) vel corticosteroides (corticosteroids) opus erit. Nuper, therapiae biologicae rituximab (rituximab), omalizumab (omalizumab), interleukin-1 inhibitors (interleukin-1 inhibitors) promissionem pro casibus duris ostenderunt.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.

Vir XXXV annorum venit cum XV dierum historia rubrarum eruptionum dolorosarum in utris femoribus et cruribus, cum dolore articulorum. Habuit infectionem tractus urinarii per hebdomadam antequam eruptiones apparuerunt. Pellis eius varias placas teneras, anulares, partim blanchabiles, rubras in utris lateribus femoribus et cruribus ostendit. Prednisolona oralis (40 mg/die) administrata est hebdomada una cum antihistaminico non‑somnolentem (fexofenadine). Intra septimanam, omnes eruptiones penitus evanuerunt. Eruptiones non amplius apparuerunt per proximos sex menses regularibus inspectionibus.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.